Pharmacokinetics in special populations

被引:14
作者
Poggesi, Italo [1 ]
Benedetti, Margherita Strolin
Whomsley, Rhys [2 ]
Le Lamer, Sophie [3 ]
Molimard, Mathieu [4 ]
Watelet, Jean-Baptiste [5 ]
机构
[1] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, I-37135 Verona, Italy
[2] Shire Pharmaceut, Biosci, Basingstoke, Hants, England
[3] UCB Pharma SA, Pharmacokinet Pharmacodynam Modeling & Simulat, Lalleud, Braine, Belgium
[4] Univ Victor Segalen, Dept Pharmacol, INSERM, U657, Bordeaux, France
[5] Univ Ghent, State Univ Ghent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Ghent, Belgium
关键词
Antiallergic drugs; pharmacokinetics; pharmacodynamics; renal impairment; hepatic impairment; demographic covariates; pregnancy; milk transfer; FUROATE NASAL SPRAY; LIVER ALCOHOL-DEHYDROGENASE; HEPATIC DRUG-METABOLISM; HISTAMINE-INDUCED WHEAL; ALLERGIC RHINITIS; CLINICAL-PHARMACOLOGY; CREATININE CLEARANCE; FLUTICASONE FUROATE; HEALTHY-VOLUNTEERS; MOMETASONE FUROATE;
D O I
10.1080/10837450902891527
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs. However, the knowledge of the physiological grounds of the pharmacokinetics can provide some insight for predicting the potential alterations and guiding the initial prescription strategies. It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter.
引用
收藏
页码:422 / 454
页数:33
相关论文
共 204 条
[1]   A pharmacokinetic profile of desloratadine in healthy adults, including elderly [J].
Affrime, M ;
Gupta, S ;
Banfield, C ;
Cohen, A .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :13-19
[2]   Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine [J].
Affrime, M ;
Banfield, C ;
Gupta, S ;
Cohen, A ;
Boutros, T ;
Thonoor, M ;
Cayen, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (Suppl 1) :21-28
[3]   Frailty: An emerging Geriatric syndrome [J].
Ahmed, Nasiya ;
Mandel, Richard ;
Fain, Mindy J. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (09) :748-753
[4]   Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation [J].
Akutsu, Tomoko ;
Kobayashi, Kaoru ;
Sakurada, Koichi ;
Ikegaya, Hiroshi ;
Furihata, Tomomi ;
Chiba, Kan .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) :72-78
[5]   Using ontogeny information to build predictive models for drug elimination [J].
Alcorn, Jane ;
McNamara, Patrick J. .
DRUG DISCOVERY TODAY, 2008, 13 (11-12) :507-512
[6]   Mechanism-based concepts of size and maturity in pharmacokinetics [J].
Anderson, B. J. ;
Holford, N. H. G. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :303-332
[7]   Scaling for size: some implications for paediatric anaesthesia dosing [J].
Anderson, BJ ;
Meakin, GH .
PAEDIATRIC ANAESTHESIA, 2002, 12 (03) :205-219
[8]  
ANDERSON GD, 2007, CLIN PHARMACOKINET, V4, P989
[9]   Pharmacokinetic studies in pregnant women [J].
Anger, G. J. ;
Piquette-Miller, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) :184-187
[10]   Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor [J].
Anthes, JC ;
Gilchrest, H ;
Richard, C ;
Eckel, S ;
Hesk, D ;
West, RE ;
Williams, SM ;
Greenfeder, S ;
Billah, M ;
Kreutner, W ;
Egan, RW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (03) :229-237